United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $2.66 Million Stock Position in Cencora, Inc. $COR

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund increased its stake in shares of Cencora, Inc. (NYSE:COR) by 174.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,500 shares of the company’s stock after acquiring an additional 5,400 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Cencora were worth $2,657,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. United Bank grew its position in Cencora by 4.5% in the 2nd quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares during the last quarter. Crestwood Advisors Group LLC increased its holdings in shares of Cencora by 18.9% during the 2nd quarter. Crestwood Advisors Group LLC now owns 1,376 shares of the company’s stock worth $413,000 after purchasing an additional 219 shares during the period. Savant Capital LLC raised its position in shares of Cencora by 8.4% during the second quarter. Savant Capital LLC now owns 8,251 shares of the company’s stock valued at $2,474,000 after buying an additional 639 shares during the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in shares of Cencora during the second quarter valued at about $4,233,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Cencora in the second quarter valued at about $448,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is owned by insiders.

Cencora Trading Down 0.4%

Shares of COR opened at $357.98 on Friday. Cencora, Inc. has a 1 year low of $251.94 and a 1 year high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The stock has a 50 day simple moving average of $354.16 and a 200-day simple moving average of $336.45. The stock has a market cap of $69.64 billion, a PE ratio of 43.03, a PEG ratio of 1.67 and a beta of 0.68.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same quarter in the previous year, the firm earned $3.73 EPS. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Analyst Ratings Changes

COR has been the topic of several research reports. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Bank of America lowered their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. TD Cowen raised their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $399.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.